Outcome Capital Continues to Expand with the Addition of Industry Veteran Stanislav Glezer, MD MBA

BOSTON–Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm today announced that Stanislav Glezer, MD MBA, has been appointed to the role of Managing Director.

Oded Ben-Joseph, PhD, MBA, Outcome’s Managing Partner commented, “On behalf of the Outcome Capital team, I congratulate Stan on this appointment as I am confident that he will be a tremendous asset to our firm and to our clients. I believe Stan’s 30 years of experience in clinical research and medical affairs roles with strong experience in R&D, regulatory, commercial, market access and other areas across a variety of medical technology and biopharmaceutical firms will assist in driving Outcome Capital’s growth strategy and elevate our overall capabilities for the benefit of our clients.”

“I am honored by the opportunity to join Outcome Capital as a Managing Director,” said Dr. Glezer. “This role is well aligned with my personal mission of improving patients’ outcomes through innovation. I look forward to partnering with medical technology and biopharmaceutical companies to help advance their products and projects to commercialization and beyond by providing advisory services, identifying potential sources of funding and supporting preparation and execution of the transactions with the right partners.”

Most recently, Dr. Glezer, was with Inogen Inc, a medical technology company offering innovative respiratory products for use in the homecare setting, where he served as an Executive Vice President, R&D and Chief Medical Officer. Under his leadership, the company has secured an MDR certification, developed and obtained 510k clearance for a couple of innovative devices, acquired a French medical technology company, and completed several clinical trials and Real World Evidence projects, resulting in peer reviewed publications and posters at international conferences. Prior to Inogen, Dr. Glezer worked for Becton, Dickinson and Company, a global medical technology company where he served as the Worldwide Vice President of Medical Affairs for Diabetes Care and had business development responsibilities. Prior to joining Becton Dickinson, Dr. Glezer served as the Chief Medical Officer at Adocia S.A. and as Vice President of Global Medical Affairs at Novo Nordisk, Inc. Earlier in his career, Dr. Glezer held a number of medical affairs and medical strategy roles of progressively increasing seniority for Sanofi S.A.

Dr. Glezer holds a Doctor of Medicine with Honors from Moscow State University of Medicine and Dentistry and an MBA from California Coast University. He has completed training in Health Economics and Clinical Research at McGill University and is currently participating in the CEO Program at Columbia University Business School.

About Outcome Capital
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.